TICEBA: TICEBA exclusively licenses ABCB5+ technology for treatment of ocular and dermal diseases
TICEBA GmbH expanded an exclusive license agreement with Boston Children’s to include the treatment of ocular and dermal diseases by targeting ABCB5, a cell-surface marker found on stem cells, developed by Markus Frank, MD, in the division of Nephrology Research.
In collaborations with Schepens Eye Research Institute and the US Department of Veterans Affairs, Frank found that ABCB5 is expressed by limbal stem cells and in the retina of the mammalian eye and is required for normal corneal and retinal development. This technology has potential for corneal regeneration to treat blindness due to limbal stem cell deficiency, and treating retinal diseases such as macular degeneration or retinitis.
In another study with collaborators at the Brigham and Women’s Hospital and US Department of Veterans Affairs, he found that using isolated human ABCB5+ dermal stem cells, co-grafted with a highly porous collagen-glycosaminoglycan scaffold, had superior regenerative wound healing capacity. This could lead to novel treatments for burns or skin diseases, and is currently being investigated in a phase I/IIA human clinical trial in the indication of chronic venous ulcers (ClinicalTrials.gov Identifier: NCT02742844).